Artiva Biotherapeutics, INC

Artiva Biotherapeutics announced its 2026 annual meeting of stockholders will be held on September 8, 2026, with deadlines for stockholder proposals and nominations set for August 1, 2026.

Artiva Biotherapeutics has appointed Diego Miralles as President and Head of R&D, while CFO Thad Huston departs.

Artiva Biotherapeutics, Inc. has entered into an underwriting agreement to raise approximately $300 million through a public offering of common stock and pre-funded warrants.

Artiva Biotherapeutics announced first-quarter 2026 financial results and highlighted positive initial clinical data for its AlloNK therapy in autoimmune diseases, alongside FDA alignment for a Phase 3 trial in rheumatoid arthritis.

Artiva Biotherapeutics, Inc. announced the appointment of Thad Huston, a seasoned finance and operations executive, as its new Chief Financial Officer, effective February 18, 2026.

Artiva Biotherapeutics, Inc. announced the appointment of Elaine Sorg, a seasoned pharmaceutical executive, as a Class I director to its Board.

Artiva Biotherapeutics announces positive initial clinical data for AlloNK in autoimmune diseases, with a planned Phase 3 trial in refractory RA.

Artiva Biotherapeutics reported a wider net loss in Q3 2025 as research and development expenses surged, while the company prioritizes its lead candidate AlloNK for refractory rheumatoid arthritis with a new Fast Track designation.

Artiva Biotherapeutics reported increased net losses and cash burn in Q2 2025, while strategically shifting its clinical focus to autoimmune diseases with its lead candidate AlloNK.

Artiva Biotherapeutics reports its financial results for the first quarter of 2025, highlighting progress in clinical trials and strategic initiatives.

Artiva Biotherapeutics reports its third quarter 2024 financial results, highlighting a shift from collaboration revenue to a focus on internal development following a successful IPO.

Artiva Biotherapeutics reports a net loss of $31.8 million for the first half of 2024, while highlighting progress in clinical trials and a successful IPO.

Artiva Biotherapeutics advances AlloNK, an allogeneic NK cell therapy, targeting autoimmune diseases and cancers, with initial data expected in the first half of 2025.

Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 29, 2026.

Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 24, 2026.

Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 21, 2026.

Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 13, 2026.

Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 16, 2026.

Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on July 10, 2026.

Artiva Biotherapeutics announces its 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and an equity incentive plan amendment.

Artiva Biotherapeutics will hold its annual stockholders meeting on June 24, 2025, to vote on director election, auditor ratification, and an equity incentive plan amendment.

Artiva Biotherapeutics is holding its annual meeting to elect a director, ratify the appointment of its auditor, and approve an amendment to its equity incentive plan.

Artiva Biotherapeutics files a registration statement to increase the aggregate number of shares offered by 6,003,000 following its initial public offering.

Artiva Biotherapeutics is seeking to raise $116.8 million through an initial public offering to advance its NK cell-based therapies for autoimmune diseases and cancers.

Artiva Biotherapeutics, a clinical-stage biotechnology company, has filed an S-1 registration statement for an initial public offering to fund the development of its natural killer (NK) cell-based therapies for autoimmune diseases and cancers.

RA Capital Management and its affiliates have disclosed an increased beneficial ownership stake in Artiva Biotherapeutics, Inc. to 37.9% through recent open market purchases.

RA Capital Management has increased its beneficial ownership in Artiva Biotherapeutics to 36.6% following a series of open market purchases.

RA Capital Management reports a significant increase in its beneficial ownership of Artiva Biotherapeutics following a $100 million public offering participation.

Viking Global Investors LP and affiliated entities have reported a 5.4% beneficial ownership stake in Artiva Biotherapeutics, Inc. following a recent underwritten offering.

BlackRock, Inc. filed an Amendment No. 1 to its Schedule 13G, reporting a 2.0% passive beneficial ownership stake in Artiva Biotherapeutics, Inc. as of June 30, 2025.

venBio Global Strategic Fund III, L.P. and its affiliated entities have reported a passive beneficial ownership of 4.9% in Artiva Biotherapeutics, Inc., holding 1,198,975 shares of common stock as of March 31, 2025.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in Artiva Biotherapeutics, Inc. as of March 31, 2025, held in the ordinary course of business.